ServiceNow R&D increased by 6.5% to $823.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 17.1%, from $703.00M to $823.00M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 20.6% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $333.00M | $358.00M | $392.00M | $414.00M | $444.00M | $456.00M | $454.00M | $492.00M | $521.00M | $549.00M | $562.00M | $606.00M | $643.00M | $626.00M | $668.00M | $703.00M | $734.00M | $750.00M | $773.00M | $823.00M |
| QoQ Change | — | +7.5% | +9.5% | +5.6% | +7.2% | +2.7% | -0.4% | +8.4% | +5.9% | +5.4% | +2.4% | +7.8% | +6.1% | -2.6% | +6.7% | +5.2% | +4.4% | +2.2% | +3.1% | +6.5% |
| YoY Change | — | — | — | — | +33.3% | +27.4% | +15.8% | +18.8% | +17.3% | +20.4% | +23.8% | +23.2% | +23.4% | +14.0% | +18.9% | +16.0% | +14.2% | +19.8% | +15.7% | +17.1% |